Laura E. Domínguez-Gallegos, Dermatological Center “Ladislao de la Pascua”, Mexico City, Mexico
Martha A. Morales-Sánchez, Dermatological Center “Ladislao de la Pascua”, Mexico City, Mexico
Fermín Jurado-Santa Cruz, Dermatological Center “Ladislao de la Pascua”, Mexico City, Mexico
Josué E. Villegas-Domínguez, Public Health Department, Medical School, Universidad del Valle de México, Veracruz, Veracruz. Mexico
Antecedents: Actinic prurigo is a rare idiopathic photodermatosis that has a markedly negative impact on the patients’ quality of life. Several therapeutic strategies are available for actinic prurigo; these strategies are aimed at controlling the patient’s lesions and associated symptoms, mainly by preventing exposure to the sunlight. Therefore, this review presents an evidence-based summary of the treatment options complementary to photoprotection for actinic prurigo. Objetive: to determine the efficacy and safety of the treatment options complementary to photoprotection for patients with AP and to assess the consistency of the findings and quality of the different studies included in this review. Material and metodh: The main electronic databases were searched for studies published up to 2018 using the search terms “actinic prurigo,” “actinic dermatitis,” and “solar prurigo”; seven articles about therapeutic interventions, including clinical trials, quasi-experimental studies, and cohort studies were identified. Results and conclusion: According to evidence, thalidomide is an effective option, followed by phototherapy, pentoxifylline and ciclosporin; however, the quality of the evidence is poor in order to carry out a metanalysis or to identify the effectiveness of the treatments in a quantitative manner, therefore, clinical trials are required to obtain more precise values of efficacy of the treatment of actinic prurigo.
Keywords: Actinic prurigo. Photodermatosis. Therapeutic.